1. Metabolic Disease

Metabolic Disease

Metabolic diseases is defined by a constellation of interconnected physiological, biochemical, clinical, and metabolic factors that directly increases the risk of cardiovascular disease, type 2 diabetes mellitus, and all cause mortality. Associated conditions include hyperuricemia, fatty liver (especially in concurrent obesity) progressing to nonalcoholic fatty liver disease, polycystic ovarian syndrome (in women), erectile dysfunction (in men), and acanthosis nigricans. Metabolic disease modeling is an essential component of biomedical research and a mandatory prerequisite for the treatment of human disease. Somatic genome editing using CRISPR/Cas9 might be used to establish novel metabolic disease models.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-108523
    LG100754 180713-37-5 99.0%
    LG100754 (UVI 2112) is a RXR dimers modulater. LG100754 acts as a RXR:RXR homodimer antagonist, but functions as a agonist towards RXR:PPARα and RXR:PPARγ heterodimers. LG100754 is an insulin sensitizer that functions through RXR.
    LG100754
  • HY-113285
    Ureidopropionic acid 462-88-4
    Ureidopropionic acid (3-Ureidopropionic acid) is a selective mitochondrial respiratory chain complex V inhibitor. Ureidopropionic acid induces the production of reactive oxygen species, delayed elevation of intracellular calcium concentration, secondary energy-dependent excitotoxicity and neurodegeneration in neurons. Ureidopropionic acid promotes neuropathological changes by impairing mitochondrial energy metabolism, oxidative stress and excitotoxicity pathways. Ureidopropionic acid can be used in studies related to 3-ureidopropionase deficiency and severe propionic aciduria.
    Ureidopropionic acid
  • HY-113369
    Cholesteryl arachidonate 604-34-2 ≥99.0%
    Cholesteryl arachidonate is an endogenous metabolite.
    Cholesteryl arachidonate
  • HY-114702
    M77976 394237-61-7 99.44%
    M77976 is a specific ATP-competitive inhibitor of PDK4 (pyruvate dehydrogenase kinase isoforms 4), with an IC50 of 648 μM. M77976 is potential for the research of obesity and diabetes.
    M77976
  • HY-126052
    Gnetol 86361-55-9 ≥98.0%
    Gnetol is a phenolic compound isolated from the root of Gnetum montanum . Gnetol potently inhibits COX-1 (IC50 of 0.78 μM) and HDAC. Gnetol is a potent tyrosinase inhibitor with an IC50 of 4.5 μM for murine tyrosinase and suppresses melanin biosynthesis. Gnetol has antioxidant, antiproliferative, anticancer and hepatoprotective activity. Gnetol also possesses concentration-dependent α-Amylase, α-glucosidase, and adipogenesis activities.
    Gnetol
  • HY-132187
    Sphingosylphosphorylcholine 1670-26-4 99.50%
    Sphingosylphosphorylcholine is a bioactive lipid and a major component of plasma high-density lipoprotein that binds to OGR1 with a Kd of 33.3 nM. Sphingosylphosphorylcholine triggers delayed phosphorylation of Smad2, upregulates α-SMA expression, and activates TRPM3. Sphingosylphosphorylcholine reduces Apoptosis and upregulates the expression of uPA and its receptor uPA-R. Sphingosylphosphorylcholine exerts anti-apoptotic, anti-cardiac hypertrophy and pro-wound healing effects. Sphingosylphosphorylcholine induces scratching behavior in mice. Sphingosylphosphorylcholine is used in studies related to atopic dermatitis, promyelocytic leukemia, heart failure, myocardial ischemia/reperfusion injury, ovarian cancer, breast cancer, pancreatic cancer, and skin wound healing disorders in genetically impaired healing diabetes.
    Sphingosylphosphorylcholine
  • HY-136742
    BACE2-IN-1 1676107-08-6 99.4%
    BACE2-IN-1 (compound 3l) is a highly selective BACE2 inhibitor with a Ki value of 1.6 nM. BACE2 inhibitors can be used to research of Type 2 Diabetes.
    BACE2-IN-1
  • HY-137167
    Guanylyl imidodiphosphate lithium 64564-03-0
    Guanylyl imidodiphosphate lithium (Gpp (NH) p lithium) is a non-hydrolyzable GTP analog. Guanylyl imidodiphosphate lithium increases adenylate cyclase activity. Guanylyl imidodiphosphate lithium binds to and irreversibly activates G proteins.
    Guanylyl imidodiphosphate lithium
  • HY-13964A
    YIL781 hydrochloride 1640226-17-0 ≥99.0%
    YIL781 hydrochloride is a potent and orally active ghrelin receptor (GHSR) antagonist. YIL781 hydrochloride produces a greater improvement in glucose homeostasis in rats. YIL781 hydrochloride inhibits the calcium response induced by ghrelin with pIC50 values of 7.90 and 8.27, respectively.
    YIL781 hydrochloride
  • HY-B0012A
    Pamidronate disodium 57248-88-1 ≥98.0%
    Pamidronate disodium (CGP 23339A), the second-generation nitrogen-containing bisphosphonate, is an inhibitor of bone loss. Pamidronate disodium significantly inhibits subchondral bone loss in early osteoarthritis by upregulating the expression of osteoprotegerin in cartilage and subchondral bone, and inhibiting the expression of RANKL and MMP-9 in both tissues, as well as TLR-4 in cartilage, thereby alleviating cartilage degeneration. Additionally, Pamidronate disodium can inhibit the signaling of Wnt and β-catenin, and is applicable for research on osteoporosis and osteosarcoma.
    Pamidronate disodium
  • HY-B0281A
    Ranitidine hydrochloride 66357-59-3 99.86%
    Ranitidine hydrochloride is a potent, selective and orally active histamine H2-receptor antagonist that inhibits gastric secretion. Ranitidine hydrochloride antagonizes Histamine (HY-B1204)-induced increases of the guinea-pig isolated rat atrium and Histamine-induced relaxations of the rat isolated uterine horn, with pA2 values of 7.2 and 6.95, respectively. Ranitidine hydrochloride inhibits breast tumor development and spread in mice.
    Ranitidine hydrochloride
  • HY-B0351R
    Taurine (Standard) 107-35-7 99.96%
    Taurine (Standard) is the analytical standard of Taurine. This product is intended for research and analytical applications. Taurine, a sulphur-containing amino acid and an organic osmolyte involved in cell volume regulation, provides a substrate for the formation of bile salts, and plays a role in the modulation of intracellular free calcium concentration. Taurine has the ability to activate autophagy in adipocytes.
    Taurine (Standard)
  • HY-B1899A
    Taurodeoxycholic acid sodium hydrate 110026-03-4 99.75%
    Taurodeoxycholic acid sodium hydrate (Sodium taurodeoxycholate monohydrate), a bile acid, is an amphiphilic surfactant molecule synthesized from cholesterol in the liver. Taurodeoxycholic acid sodium hydrate activates the S1PR2 pathway in addition to the TGR5 pathway.
    Taurodeoxycholic acid sodium hydrate
  • HY-N0415S
    Trigonelline-d3 chloride 99.91%
    Trigonelline-d3 (chloride) is the deuterium labeled Trigonelline chloride. Trigonelline chloride, an alkaloid with potential antidiabetic activity, is present in considerable amounts in coffee. Trigonelline chloride has anti-HSV-1 , antibacterial, and antifungal activities.
    Trigonelline-d3 chloride
  • HY-P99801
    Pascolizumab 331243-22-2 ≥99.0%
    Pascolizumab (SB-240683) is a humanized anti-IL-4 monoclonal antibody. Pascolizumab has the potential for the research of asthma.
    Pascolizumab
  • HY-101981R
    Uridine 5'-monophosphate (Standard) 58-97-9 99.83%
    Uridine 5'-monophosphate (Standard) is the analytical standard of Uridine 5'-monophosphate. This product is intended for research and analytical applications. Uridine 5'-monophosphate (5'-Uridylic acid) is an orally active mitochondrial ATP-dependent potassium channel activator that has a protective effect on the heart. Uridine 5'-monophosphate can promote the synthesis of CDP-choline and induce apoptosis in intestinal epithelial cells, which is beneficial for gut development and reduces diarrhea.
    Uridine 5'-monophosphate (Standard)
  • HY-B0285AR
    Amiloride hydrochloride (Standard) 2016-88-8 99.59%
    Amiloride (hydrochloride) (Standard) is the analytical standard of Amiloride (hydrochloride). This product is intended for research and analytical applications. Amiloride hydrochloride (MK-870 hydrochloride) is an inhibitor of both epithelial sodium channel (ENaC) and urokinase-type plasminogen activator receptor (uTPA). Amiloride hydrochloride is a blocker of polycystin-2 (PC2; TRPP2) channel.
    Amiloride hydrochloride (Standard)
  • HY-B0445GL
    NAD+ (GMP Like) 53-84-9 99.79%
    NAD+ (GMP Like) is NAD+ (HY-B0445) produced by using GMP like guidelines. GMP Like small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. NAD+ is a coenzyme composed of ribosylnicotinamide 5'-diphosphate coupled to adenosine 5'-phosphate by pyrophosphate linkage.
    NAD+ (GMP Like)
  • HY-N0384S2
    Homovanillic acid-d5 53587-32-9 99.0%
    Homovanillic acid-d5 (Vanilacetic acid-d5) is the deuterium labeled Homovanillic acid (HY-N0384). Homovanillic acid (Vanilacetic acid) is a dopamine metabolite found to be associated with aromatic L-amino acid decarboxylase deficiency, celiac disease, growth hormone deficiency, and sepiapterin reductase deficiency.
    Homovanillic acid-d5
  • HY-P10586A
    Macrophage-activating lipopeptide 2 TFA 99.83%
    Macrophage-activating lipopeptide 2 TFA is an agonist of Toll like receptors TLR-2/TLR-6. Macrophage-activating lipopeptide-2 enhances endothelial nitric oxide synthase (eNOS) phosphorylation and endothelial cell release of NO, thereby improving vasodilation. Macrophage-activating lipopeptide-2 enhances endothelial adhesion of white blood cells and improve perfusion recovery and collateral growth in the hind limbs of hypercholesterolemic Apoe deficient mice undergoing experimental femoral artery ligation (FAL).
    Macrophage-activating lipopeptide 2 TFA
Cat. No. Product Name / Synonyms Application Reactivity